BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (Butalbital, Aspirin, Caffeine, and Codeine Phosphate) Nursing Considerations

What is the generic name?

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

What is the Trade Name for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE?

Butalbital, Aspirin, Caffeine, and Codeine Phosphate

What are the Indications for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE?

• 1 INDICATIONS AND USAGE Butalbital, aspirin, caffeine, and codeine phosphate capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache, when non-opioid analgesic and alternative treatments are inadequate. Butalbital, aspirin, caffeine, and codeine phosphate capsules are a combination of butalbital, a barbiturate, aspirin, a nonsteroidal anti-inflammatory drug, caffeine, a methylxanthine, and codeine phosphate, an opioid agonist, and is indicated for the management of the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve butalbital, aspirin, caffeine, and codeine phosphate capsules for use in patients for whom alternative treatment options (e.g., non-opioid analgesics) ( 5.1 ): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids and butalbital, even at recommended doses [see Warnings and Precautions (5.1) ] , reserve butalbital, aspirin, caffeine, and codeine phosphate capsules for use in patients for whom alternative treatment options (e.g., non-opioid, non-barbiturate analgesics): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia

References: https://open.fda.gov/